Expression of CXCL11 & TEMRA in Serum of Vitiligo Patients Treated With Narrow-band UVB
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
- 主要终点
- Change in serum CXCL11 & TEMRA levels
研究概览
简要总结
this is a prospective, randomized controlled trial (RCT) investigating the immunological effects of narrowband UVB (NB-UVB) phototherapy-both as monotherapy and in combination with oral mini-pulse (OMP) steroids-in non-segmental vitiligo patients. The study evaluates changes in CXCL11 (a chemokine involved in T-cell recruitment) and TEMRA (terminally differentiated effector memory T cells re-expressing CD45RA) levels in serum before and after treatment.
详细描述
Design:
Randomized controlled trial (RCT) with two parallel arms.
Duration: Six months (including baseline and follow-up assessments).
Setting: Outpatient dermatology clinic at Assiut University Hospital, Egypt.
Objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinically diagnosed non-segmental vitiligo (stable for ≥3 months).
- •Fitzpatrick skin types III-V (common in the Egyptian population).
- •No recent systemic therapy for vitiligo (within the last 3 months).
排除标准
- •Photosensitivity disorders (e.g., lupus, porphyria).
- •Pregnancy or breastfeeding.
- •Active infections, malignancies, or immunosuppressive conditions.
- •History of hypertrophic scarring or melanoma.
研究组 & 干预措施
Group 1 (NB-UVB Monotherapy)
Standard phototherapy without additional systemic treatment.
干预措施: NB-UVB twice weekly (Radiation)
Group 2 (NB-UVB + OMP Steroids)
Combination therapy of NB-UVB + OMP Steroids to enhance immunosuppression and repigmentation.
干预措施: NB-UVB + dexamethasone (2.5-3 mg/week) (Other)
结局指标
主要结局
Change in serum CXCL11 & TEMRA levels
时间窗: 6 months
Measured via ELISA before and after treatment.
次要结局
未报告次要终点
研究者
ALZAHRA MOAHMED MOHAMED ABDELHAFEZ
resident at the dermatology Surgery department
Assiut University